Last reviewed · How we verify
Raltegravir for the last 2 weeks
At a glance
| Generic name | Raltegravir for the last 2 weeks |
|---|---|
| Sponsor | University Hospital, Geneva |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Acute hepatitis A
- Influenza
- Proctitis herpes
- Shingles
- Wrist injury
- Back pain
Key clinical trials
- Research In Viral Eradication of HIV Reservoirs (PHASE2)
- Patient Preference, Sleep Quality, and Anxiety/Depression: A Comparison of Raltegravir and Efavirenz (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Raltegravir for the last 2 weeks CI brief — competitive landscape report
- Raltegravir for the last 2 weeks updates RSS · CI watch RSS
- University Hospital, Geneva portfolio CI